Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4058776 | 1.00 | FNTA (0.32) | FNTAFNTB | |
| SCHEMBL2495853 | 1.00 | FNTA (0.32) | FNTAFNTB | |
| SCHEMBL2495854 | 1.00 | FNTA (0.32) | FNTAFNTB | |
| SCHEMBL2495856 | 1.00 | FNTA (0.32) | FNTAFNTB | |
| SCHEMBL14226490 | 0.81 | — | — | |
| SCHEMBL13093838 | 0.81 | MEN1 (0.33) | — | |
| SCHEMBL13745833 | 0.80 | FNTA (0.33) | FNTAFNTB | |
| SCHEMBL5746283 | 0.80 | GRIK1 (0.41) | FNTAFNTB | |
| SCHEMBL17946581 | 0.80 | — | — | |
| SCHEMBL2759244 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180215748-A1 | EPOTHILONE B AND DICTYOSTATIN ANALOGS, THEIR PREPARATION AND USE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2018-08-02 | — | — | US | disclosed |
| US-20150175587-A1 | SYNTHESIS OF EPOTHILONES, INTERMEDIATES THERETO AND ANALOGUES THEREOF | SLOAN KETTERING INST CANCER (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150175587-A1 | SYNTHESIS OF EPOTHILONES, INTERMEDIATES THERETO AND ANALOGUES THEREOF | SLOAN KETTERING INST CANCER (US) | 2015-06-25 | — | — | US | disclosed |
| US-20140213618-A1 | SYNTHESIS OF EPOTHILONES, INTERMEDIATES THERETO AND ANALOGUES THEREOF | SLOAN KETTERING INST CANCER (US) | 2014-07-31 | — | — | US | disclosed |
| US-8513429-B2 | Synthesis of epothilones, intermediates thereto and analogues thereof | SLOAN-KETTERING INSITUTE FOR CANCER RESEARCH (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513429-B2 | Synthesis of epothilones, intermediates thereto and analogues thereof | SLOAN-KETTERING INSITUTE FOR CANCER RESEARCH (US) | 2013-08-20 | — | — | US | disclosed |
| US-20120316348-A1 | SYNTHESIS OF EPOTHILONES, INTERMEDIATES THERETO AND ANALOGUES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2012-12-13 | — | — | US | disclosed |
| US-20120316348-A1 | SYNTHESIS OF EPOTHILONES, INTERMEDIATES THERETO AND ANALOGUES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2012-12-13 | — | — | US | disclosed |
| US-8110590-B2 | Synthesis of epothilones, intermediates thereto and analogues thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2012-02-07 | — | — | US | disclosed |
| US-7875638-B2 | desoxyepothilone A and B; Fludelone; anticarcinogenic agents; drug resistance; water solubility for formulability; industrial scale; cytotoxic or growth inhibitory effects on CAG myeloma cells lines; ability to polymerize tubulin; minimum toxicity; isomerization of the double bonds in the ring | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2011-01-25 | — | — | US | disclosed |
| US-7384964-B2 | Synthesis of epothilones, intermediates thereto, analogues and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2008-06-10 | — | — | US | disclosed |
| EP-1874752-A1 | PROCESS FOR THE PREPARATION OF 9,10-DEHYDRO-12,13-DESOXYEPOTHILONE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2008-01-09 | — | — | EP | disclosed |
| US-7238816-B2 | Preparation of epothilone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238816-B2 | Preparation of epothilone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238816-B2 | Preparation of epothilone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-20070032534-A1 | 12,13-desoxyepothilones, used as anticarcinogenic agents | DANISHEFSKY SAMUEL J | 2007-02-08 | — | — | US | disclosed |
| US-20060241156-A1 | Preparation of epothilone derivatives | KOSAN BIOSCIENCES, INC. | 2006-10-26 | — | — | US | disclosed |
| US-20060241156-A1 | Preparation of epothilone derivatives | KOSAN BIOSCIENCES, INC. | 2006-10-26 | — | — | US | disclosed |
| US-20060241156-A1 | Preparation of epothilone derivatives | KOSAN BIOSCIENCES, INC. | 2006-10-26 | — | — | US | disclosed |
| WO-2006111491-A1 | PROCESS FOR THE PREPARATION OF 9,10-DEHYDRO-12,13-DESOXYEPOTHILONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316348-A1 | SYNTHESIS OF EPOTHILONES, INTERMEDIATES THERETO AND ANALOGUES THEREOF | DHPS, THPO, CYP11B1 | FNTA 73/4885FNTB 294/4885 |
| US-20150175587-A1 | SYNTHESIS OF EPOTHILONES, INTERMEDIATES THERETO AND ANALOGUES THEREOF | DHPS, THPO, CYP11B1 | FNTA 73/4885FNTB 294/4885 |
| US-20180215748-A1 | EPOTHILONE B AND DICTYOSTATIN ANALOGS, THEIR PREPARATION AND USE | DHPS, EPOR, THPO | FNTA 313/4885FNTB 74/4885 |
| US-20060241156-A1 | Preparation of epothilone derivatives | EPOR, DHPS, HCCS | FNTA 1377/4885FNTB 1779/4885 |
| US-20140213618-A1 | SYNTHESIS OF EPOTHILONES, INTERMEDIATES THERETO AND ANALOGUES THEREOF | DHPS, THPO, CYP11B1 | FNTA 73/4885FNTB 294/4885 |
| US-20070032534-A1 | 12,13-desoxyepothilones, used as anticarcinogenic agents | GSTA1, GSTO1, GSTA2 | FNTA 158/4885FNTB 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.